Immunome (IMNM) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
25 Jun, 2026Opening remarks and agenda
Meeting called to order at 9:00 A.M. Pacific Time, with board members, executive leadership, and auditors present.
Voting instructions provided, with clarification on proxy and online voting procedures.
Inspector of Elections appointed and record date for voting established as April 16, 2026.
Notice of meeting mailed to all stockholders of record, with 113,249,519 shares outstanding and a quorum confirmed.
Four proposals outlined for consideration: director elections, auditor ratification, executive compensation, and vote frequency.
Board and executive committee updates
Election of three Class III directors for terms expiring at the 2029 annual meeting: James Boylan, Philip Wagenheim, and Sandra Swain.
Shareholder proposals
Advisory vote on executive compensation and on the frequency of such votes included among the proposals.
Latest events from Immunome
- Varegacestat nears a 2027 FDA decision as ADC development advances on IM-1021 data.IMNM
3rd Annual Guggenheim Healthcare Innovation Conference - Varegacestat advanced through review as pipeline trials expanded and runway extended into 2028.IMNM
Q3 2026 - Varegacestat delivered strong RINGSIDE results as launch preparations and ADC development advance.IMNM
H.C. Wainwright 28th Annual Global Investment Conference - Varegacestat's strong Phase 3 results and a differentiated ADC platform drive oncology innovation.IMNM
Corporate presentation - FDA accepted NDA for varegacestat; Q2 net loss $73.1M, cash $520M, pipeline advancing.IMNM
Q2 2026 - Advancing global ADC and targeted therapy pipeline, with pivotal AL102 data expected in 2025.IMNM
Guggenheim Securities Inaugural Healthcare Innovation Conference - Varegacestat nears pivotal data with strong differentiation, while ADC innovation advances.IMNM
Guggenheim Securities 2nd Annual Healthcare Innovation Conference - Varegacestat shows strong efficacy as launch nears; ADC pipeline and cash runway support growth.IMNM
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Varegacestat achieved best-in-class efficacy and safety in Phase 3 desmoid tumor trial.IMNM
Study Result